Korean J Pain 2023; 36(2): 147-148
Published online April 1, 2023 https://doi.org/10.3344/kjp.23082
Copyright © The Korean Pain Society.
Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Correspondence to:Jong Yeon Park
Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
Tel: +82-2-3010-3867, Fax: +82-2-3010-6958, E-mail: firstname.lastname@example.org
Handling Editor: Francis S. Nahm
Received: March 9, 2023; Revised: March 15, 2023; Accepted: March 15, 2023
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
In the last issue of the Korean Journal of Pain, an experimental research paper about the heparanase and cancer pain progression was presented . Heparanase treatment aggravated mechanical allodynia, cold response, and spontaneous pain. Additionally, the contents of inflammatory cytokines (TNF-α, NF-κB, IL-1β, and IL-6) was increased, and programmed death-ligand 1 (PD-L1) level was decreased in tumor tissue. Inversely, the heparanase inhibitor (SST0001) exhibited opposite results .
Programmed cell death protein 1, also known as PD-1, is a type I transmembrane glycoprotein and a cell surface receptor. PD-1 is broadly presented on cytotoxic T cells, regulatory T cells, B cells, natural killer cells, microglia, macrophages, and certain types of neurons [2–4].
PD-1 has a role in suppressing the inflammatory actions of T cells. Therefore, the immune system is down-regulated, self-tolerance is promoted, autoimmune diseases are attenuated, and killing actions against cancer cells by the immune system could be prevented .
PD-1 is an essential and negatively acting regulator related to diverse biological effects and diseases, such as cancer immunotherapy, brain tumors, Alzheimer’s disease, stroke, multiple sclerosis and cognitive dysfunctions [6,7].
PD-1 signaling modulates synaptic plasticity, synaptic transmission, and neuronal excitability in neurons . The neuronal signaling of PD-1 regulates pain by modulating dephosphorylating transient receptor potential subtype V1 (TRPV1) , GABAergic neurotransmission , and sodium/potassium channels . In an experiment with
On the other hand, PD-1 inhibitors, a newly developed class of anticancer medicine that block PD-1, could activate the immune system to attack cancer cells and could be used to treat special types of cancers . For example, Pembrolizumab is a humanized IgG4 isotype antibody, and it blocks a protective mechanism of cancer cells and allows the immune system to destroy cancer cells. It targets the PD-1 receptor of lymphocytes and acts by targeting the cellular pathway of proteins, known as PD-1/PD-L1, found on the immune cells and certain cancer cells. Pembrolizumab is used as an immunotherapy medicine for treatments of lung cancer, head and neck cancer, melanoma, Hodgkin’s lymphoma, gastric cancer, cervical cancer, and some kinds of breast cancer. The common adverse effects of Pembrolizumab are tiredness, skin rash, severe itching of the skin, gastrointestinal disturbance, retching, joint pain, muscular pain, and limb pain. During the treatment of cancer with PD-1 inhibitors, joint pain or muscle pain could occur.
Clinically it’s very difficult to differentiate PD-1 inhibitor-induced pain from cancer pain itself. However, we should bear in mind that some anticancer medicines, such as PD-1 inhibitors, could aggravate the patients’ pain and unpleasant feelings.
Data sharing is not applicable to this article as no datasets were generated or analyzed for this paper.
No potential conflict of interest relevant to this article was reported.
No funding to declare.
Jong Yeon Park: Concept/writing/manuscript preparation.